Abpro, NJCTTQ to develop bispecific antibodies in immuno-oncology

Antibody company Abpro Corp. (Woburn, Mass.) has partnered with Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. (NJCTTQ) to use Abpro’s DiversImmune antibody discovery platform to develop multiple bispecific antibodies, including T cell engagers, to treat cancer.

Abpro is eligible for up to $4 billion in the deal, which includes $60 million in near term R&D funding, plus undisclosed milestones and royalties...